Download by
Scanning QR Code
No Data
US Stock MarketDetailed Quotes
CDTX Cidara Therapeutics
Watchlist
0.9422
+0.0022+0.23% Close 09/29 16:00 ET
0.9500+0.0078+0.83%
Post 18:11 ET
0.9780High0.9250Low228.12KVolume
0.9485Open0.9400Pre Close216.11KTurnover0.30%Turnover RatioLossP/E (TTM)85.04MMarket Cap2.100052wk HighLossP/E (Static)90.25MShares0.460152wk Low5.51P/B70.76MFloat Cap19.1300Historical High--Dividend TTM75.10MShs Float0.4000Historical Low--Div YieldTTM5.64%Amplitude0.9470Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Cidara Therapeutics Company
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.
News
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunoth
Cidara Therapeutics to Present New Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023
Cidara Therapeutics, Inc. (Nasdaq: CDTX) today announced that it will present new data on its drug-Fc conjugate (DFC) candidate, CD388, in an oral presentation and two poster presentations at IDWeek 2023.
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Surges 32% Yet Its Low P/S Is No Reason For Excitement
Those holding Cidara Therapeutics, Inc. (NASDAQ:CDTX) shares would be relieved that the share price has rebounded 32% in the last thirty days, but it needs to keep going to repair the recent damage it